These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3991531)

  • 1. Bone scan in haemodialysis patients: relation to hyperparathyroidism and aluminium toxicity.
    Tielemans C; Wens R; Collart F; Dratwa M; Smeyers-Verbeke J; Van Hooff I; De Roy G; Bergmann P; Verbeelen D
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():399-402. PubMed ID: 3991531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of 99mTc pyrophosphate bone scintigraphy in the survey of dialysis osteodystrophy.
    Vanherweghem JL; Schoutens A; Bergman P; Dhaene M; Goldman M; Fuss M; Kinnaert P
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():431-4. PubMed ID: 2986102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cells indices and aluminium toxicity in haemodialysis patients.
    Tielemans C; Kalima L; Collart F; Wens R; Smeyers-Verbeke J; Verbeelen D; Dratwa M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():395-8. PubMed ID: 3991530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal osteodystrophy: aluminium and secondary hyperparathyroidism].
    de Vernejoul MC
    Rev Prat; 1990 Mar; 40(7):613-8. PubMed ID: 2326587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early effects of aluminium deposition and dialysis on bone in chronic renal failure: a cross-sectional bone-histomorphometric study.
    Dahl E; Nordal KP; Halse J; Flatmark A
    Nephrol Dial Transplant; 1990; 5(6):449-56. PubMed ID: 2122323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum bone content in dialysis osteodystrophy with secondary hyperparathyroidism.
    Pizzarelli F; Ballanti P; Costantini S; Mocetti P; Giordano R; Della Rocca C; Fabrizi F; Bonucci E; Maggiore Q
    Miner Electrolyte Metab; 1988; 14(2-3):129-34. PubMed ID: 3380068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone scintigraphy in uremic osteodystrophy].
    Mátyus J; Bakó G; Bajnok L; Kakuk G; Leövey A
    Orv Hetil; 1989 Dec; 130(51):2731-5. PubMed ID: 2601956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periosteal new bone in patients on intermittent haemodialysis: an early indicator of aluminium-induced osteomalacia?
    Chambers SE; Winney RJ
    Clin Radiol; 1985 Mar; 36(2):163-8. PubMed ID: 4064494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bone scan in patients with aluminium-associated bone disease.
    Botella J; Gallego JL; Fernandez-Fernandez J; Sanz-Guajardo D; de Miguel A; Ramos J; Franco P; Enriques R; Sanz-Moreno C
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():403-9. PubMed ID: 3991532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of aluminium on the effect of 1 alpha (OH)D3 on renal osteodystrophy.
    Shimada H; Nakamura M; Marumo F
    Nephron; 1983; 35(3):163-70. PubMed ID: 6633756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
    Kohara N
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of 99mTc pyrophosphate bone scintigraphy for vitamin D trials in uraemia.
    Vanherweghem JL; Dhaene M; Tielemans C; Dratwa M; Verbanck P; Bergmann P; Schoutens A; Fuss M
    Proc Eur Dial Transplant Assoc; 1981; 18():648-51. PubMed ID: 6276883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
    Heaf JG; Nielsen LP
    Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of renal osteodystrophy in haemodialysis patients in Saudi Arabia.
    Huraib S; Souqqiyeh MZ; Aswad S; al-Swailem AR
    Nephrol Dial Transplant; 1993; 8(7):603-8. PubMed ID: 8396743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of photon absorption densitometry of the bone in uremic osteodystrophy].
    Bichi Secchi E; Baldelli S; Argalia G; Pigini G; Lombardi M; Procaccini G; Bordoni E
    Radiol Med; 1987 Apr; 73(4):265-70. PubMed ID: 3575801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localisation of aluminium by histochemical and electron probe x-ray microanalytical techniques in bone tissue of cases of renal osteodystrophy.
    Smith PS; McClure J
    J Clin Pathol; 1982 Nov; 35(11):1283-93. PubMed ID: 7142436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.